Erinoff L, MacPhail R C, Heller A, Seiden L S
Brain Res. 1979 Mar 23;164:195-205. doi: 10.1016/0006-8993(79)90015-5.
This experiment examined the effects on locomotor activity of intraventricular 6-hydroxydopamine (6-OHDA) administered to developing and adult rats. 6-OHDA was administered subsequent to pargyline treatment at 3 and 6 days of age; or 6-OHDA was administered subsequent to desmethylimipramine (DMI) treatment (6-OHDA/DMI) at 3 and 6 days of age, 11 and 14 days of age, 20 and 23 days of age, or 46 and 48 days of age. Locomotor activity of vehicle-treated rats assessed in stabilimeter cages peaked between 14 and 16 days of age and subsequently declined to levels characteristic of the adult. Treatment with pargyline and 6-OHDA at 3 days of age, or 6-OHDA/DMI at 3 and 6 or 11 and 14 days of age, did not alter the early rise in locomotor activity but prevented the decline in activity normally seen during the third and fourth weeks of life. When tested as adults, locomotor activity was greater in rats that had been treated with 6-OHDA/DMI at 3 and 6 and at 11 and 14 days of age than in those that had been treated at 20 and 23 days of age. Treatment with 6-OHDA/DMI at 46 and 48 days of age was without significant effect on locomotor activity. 6-OHDA (with pargyline pretreatment) produced large decreases in NE content in telencephalon and diencephalon and in dopamine (DA) content in striatum. 6-OHDA-DMI also produced large decreases in DA content in striatum and, in some of the treatment groups, only small decreases in norepinephrine (NE) content in telencephalon, diencephalon, and brain stem. These data suggest that the maturation of neuronal systems utilizing dopamine as a neurotransmitter is essential for the suppression of locomotor activity normally seen during development. The data further suggest that dopamine depletion per se does not lead to increased locomotor activity, but rather it is the destruction of dopamine-containing fibers prior to the normal period of locomotor suppression that increases locomotor activity.
本实验研究了向发育中的大鼠和成年大鼠脑室内注射6-羟基多巴胺(6-OHDA)对其运动活性的影响。在3日龄和6日龄时,于帕吉林治疗后注射6-OHDA;或者在3日龄和6日龄、11日龄和14日龄、20日龄和23日龄或46日龄和48日龄时,于去甲丙咪嗪(DMI)治疗后注射6-OHDA(6-OHDA/DMI)。在平衡笼中评估的溶剂处理大鼠的运动活性在14至16日龄时达到峰值,随后下降至成年大鼠的特征水平。在3日龄时用帕吉林和6-OHDA治疗,或在3日龄和6日龄、11日龄和14日龄时用6-OHDA/DMI治疗,并未改变运动活性的早期升高,但阻止了通常在生命第三和第四周出现的运动活性下降。当作为成年大鼠进行测试时,在3日龄和6日龄以及11日龄和14日龄接受6-OHDA/DMI治疗的大鼠的运动活性高于在20日龄和23日龄接受治疗的大鼠。在46日龄和48日龄时用6-OHDA/DMI治疗对运动活性无显著影响。6-OHDA(经帕吉林预处理)使端脑和间脑中的去甲肾上腺素(NE)含量以及纹状体中的多巴胺(DA)含量大幅降低。6-OHDA-DMI也使纹状体中的DA含量大幅降低,并且在一些治疗组中,端脑、间脑和脑干中的去甲肾上腺素(NE)含量仅略有降低。这些数据表明,利用多巴胺作为神经递质的神经元系统的成熟对于发育过程中通常出现的运动活性抑制至关重要。数据进一步表明,多巴胺耗竭本身不会导致运动活性增加,而是在正常运动抑制期之前含多巴胺纤维的破坏会增加运动活性。